Furthermore, considering that PD-L1 is also involved in tumor “immune escape”, and plays a role in tumor growth and proliferation by affecting mitogen-activated protein kinase (MAPK) pathway [14,15], atezolizumab and other anti-PD-L1 monoclonal antibodies (mAbs) can efficiently inhibit tumor growth by exploiting different mechanisms of action. This evidence concerns the gene WNK2 and neoplasm.